• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤标志物联合检测对恶性胸腔积液的诊断准确性:一项更新的荟萃分析。

Diagnostic Accuracy of Combinations of Tumor Markers for Malignant Pleural Effusion: An Updated Meta-Analysis.

机构信息

Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

出版信息

Respiration. 2017;94(1):62-69. doi: 10.1159/000468545. Epub 2017 Apr 21.

DOI:10.1159/000468545
PMID:28427079
Abstract

BACKGROUND

The role of combinations of tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125, 15-3, and 19-9, and CYFRA 21-1 (a fragment of cytokeratin 19) in diagnosing malignant pleural effusion (MPE) has not been clearly established.

OBJECTIVES

This meta-analysis was performed to establish the overall diagnostic accuracies of combinations of these pleural fluid tumor markers for MPE.

METHODS

The PubMed, Ovid, Embase, Web of Science, and Cochrane bibliographic databases were searched. Sensitivity, specificity, and other measures of the accuracy of combinations of pleural CEA, CA 125, CA 15-3, CA 19-9, and CYFRA 21-1 in the diagnosis of MPE were pooled after a systematic review of English-language studies.

RESULTS

Twenty studies met the inclusion criteria. For pleural fluid tumor marker combinations including more than 3 studies, the summary estimates of the sensitivity/specificity for diagnosing MPE were as follows: CEA + CA 125, 0.65/0.98; CEA + CA 15-3, 0.64/0.98; CEA + CA 19-9, 0.58/0.98; CEA + CYFRA 21-1, 0.82/0.92; and CA 15-3 + CYFRA 21-1, 0.88/0.94.

CONCLUSIONS

In patients with undiagnosed pleural effusion, the combinations of positive pleural CEA + CA 15-3 and CEA + CA 19-9 are highly suspicious for pleural malignancy, but the sensitivity of these tests is poor. Therefore, their routine role in the diagnostic algorithm of these patients is questionable, and management decisions should depend on positive cytological or biopsy results from the pleura.

摘要

背景

癌胚抗原(CEA)、糖类抗原(CA)125、15-3、19-9 和细胞角蛋白 19 片段(CYFRA 21-1)等肿瘤标志物联合检测在恶性胸腔积液(MPE)诊断中的作用尚未明确。

目的

本研究旨在评估这些胸腔积液肿瘤标志物联合检测在 MPE 诊断中的总体准确性。

方法

通过系统检索 PubMed、Ovid、Embase、Web of Science 和 Cochrane 文献数据库,收集并评估了英文文献中关于胸腔 CEA、CA 125、CA 15-3、CA 19-9 和 CYFRA 21-1 联合检测对 MPE 诊断价值的研究。

结果

共纳入 20 项研究。对于包含 3 项以上研究的肿瘤标志物联合检测,诊断 MPE 的汇总敏感度/特异度分别为:CEA+CA 125,0.65/0.98;CEA+CA 15-3,0.64/0.98;CEA+CA 19-9,0.58/0.98;CEA+CYFRA 21-1,0.82/0.92;CA 15-3+CYFRA 21-1,0.88/0.94。

结论

对于不明原因胸腔积液患者,如果胸腔积液 CEA+CA 15-3 和 CEA+CA 19-9 同时为阳性,则高度怀疑为胸膜恶性肿瘤,但这些检测的敏感度较差。因此,在这些患者的诊断算法中,常规使用这些检测的作用值得质疑,管理决策应取决于胸膜的阳性细胞学或活检结果。

相似文献

1
Diagnostic Accuracy of Combinations of Tumor Markers for Malignant Pleural Effusion: An Updated Meta-Analysis.肿瘤标志物联合检测对恶性胸腔积液的诊断准确性:一项更新的荟萃分析。
Respiration. 2017;94(1):62-69. doi: 10.1159/000468545. Epub 2017 Apr 21.
2
Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis.肿瘤标志物对恶性胸腔积液的诊断准确性:一项荟萃分析。
Thorax. 2008 Jan;63(1):35-41. doi: 10.1136/thx.2007.077958. Epub 2007 Jun 15.
3
Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis.胸腔积液患者中胸腔积液癌胚抗原和细胞角蛋白片段21-1的诊断效用:一项系统评价和荟萃分析
J Clin Lab Anal. 2007;21(6):398-405. doi: 10.1002/jcla.20208.
4
Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.肿瘤标志物对肺腺癌相关恶性胸腔积液的诊断价值:一项验证性研究和Meta分析
Int J Clin Oncol. 2017 Apr;22(2):283-290. doi: 10.1007/s10147-016-1073-y. Epub 2016 Dec 18.
5
Diagnostic performance of CTLA-4, carcinoembryonic antigen and CYFRA 21-1 for malignant pleural effusion.CTLA-4、癌胚抗原和细胞角蛋白19片段对恶性胸腔积液的诊断效能
Postgrad Med. 2017 Aug;129(6):644-648. doi: 10.1080/00325481.2017.1331112. Epub 2017 May 19.
6
Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1.CD66c在肺腺癌相关恶性胸腔积液中的诊断效能:与癌胚抗原、糖类抗原19-9及细胞角蛋白19片段的比较
Pathology. 2015 Feb;47(2):123-9. doi: 10.1097/PAT.0000000000000215.
7
Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: Diagnostic cancer biomarkers.胸腔 CEA、CA-15-3、CYFRA 21-1、CA-19-9、CA-125 鉴别良恶性胸腔积液:诊断癌症的生物标志物。
Int J Biol Markers. 2023 Jun;38(2):81-88. doi: 10.1177/03936155231158661. Epub 2023 Mar 21.
8
Pleurodesis for malignant pleural effusions.恶性胸腔积液的胸膜固定术
Cochrane Database Syst Rev. 2004(1):CD002916. doi: 10.1002/14651858.CD002916.pub2.
9
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
10
Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis.癌胚抗原和细胞角蛋白-19片段用于评估非小细胞肺癌的治疗反应:一项系统评价和荟萃分析
Br J Cancer. 2017 Apr 11;116(8):1037-1045. doi: 10.1038/bjc.2017.45. Epub 2017 Mar 9.

引用本文的文献

1
Innovative Biomarkers for Diagnosing Malignant Ascites in Liver Cancer.用于诊断肝癌恶性腹水的创新生物标志物。
Onco Targets Ther. 2025 Aug 11;18:865-872. doi: 10.2147/OTT.S527224. eCollection 2025.
2
Elevated tumour markers in the pleural effusion of a patient with spontaneous esophageal rupture: a rare case report.自发性食管破裂患者胸腔积液中肿瘤标志物升高:一例罕见病例报告
J Cardiothorac Surg. 2025 Jul 14;20(1):301. doi: 10.1186/s13019-025-03539-y.
3
Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion.
外泌体miR-182-5p是恶性胸腔积液的一种潜在诊断标志物。
Transl Lung Cancer Res. 2025 Apr 30;14(4):1138-1148. doi: 10.21037/tlcr-2024-1205. Epub 2025 Apr 16.
4
Interleukin -39 Expression in Pleural Effusion and Its Diagnostic Value for Tuberculous Pleurisy.白细胞介素-39在胸腔积液中的表达及其对结核性胸膜炎的诊断价值
J Inflamm Res. 2025 Apr 5;18:4755-4770. doi: 10.2147/JIR.S488017. eCollection 2025.
5
Diagnostic accuracy of pleural fluid carbohydrate antigen 72-4 for malignant pleural effusion: a systematic review and meta-analysis.胸腔积液中糖类抗原72-4对恶性胸腔积液的诊断准确性:一项系统评价和荟萃分析
Transl Cancer Res. 2025 Feb 28;14(2):1237-1245. doi: 10.21037/tcr-24-1664. Epub 2025 Feb 26.
6
Tumor Markers in Pleural Fluid: A Comprehensive Study on Diagnostic Accuracy.胸液中的肿瘤标志物:诊断准确性的综合研究
Diagnostics (Basel). 2025 Jan 17;15(2):204. doi: 10.3390/diagnostics15020204.
7
Malignant pleural disease.恶性胸膜疾病
Breathe (Sheff). 2023 Dec;19(4):230145. doi: 10.1183/20734735.0145-2023. Epub 2024 Feb 13.
8
Pleural fluid carbohydrate antigen 72-4 and malignant pleural effusion: a diagnostic test accuracy study.胸腔积液糖类抗原 72-4 与恶性胸腔积液:一项诊断试验准确性研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666231222333. doi: 10.1177/17534666231222333.
9
A simple and efficient clinical prediction scoring system to identify malignant pleural effusion.一种简单而有效的临床预测评分系统,用于识别恶性胸腔积液。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666231223002. doi: 10.1177/17534666231223002.
10
Development and validation of a machine learning model for differential diagnosis of malignant pleural effusion using routine laboratory data.基于常规实验室数据的机器学习模型对恶性胸腔积液进行鉴别诊断的建立与验证。
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231208632. doi: 10.1177/17534666231208632.